175 related articles for article (PubMed ID: 36571670)
1. Tremelimumab: First Approval.
Keam SJ
Drugs; 2023 Jan; 83(1):93-102. PubMed ID: 36571670
[TBL] [Abstract][Full Text] [Related]
2. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Patel TH; Brewer JR; Fan J; Cheng J; Shen YL; Xiang Y; Zhao H; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
Clin Cancer Res; 2024 Jan; 30(2):269-273. PubMed ID: 37676259
[TBL] [Abstract][Full Text] [Related]
5. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
8. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.
Song X; Kelley RK; Green M; Standifer N; Lim K; Zhou D; Dunyak J; Negro A; Kurland JF; Ren S; Khan AA; Gibbs M; Abou-Alfa GK
Clin Pharmacol Ther; 2023 Oct; 114(4):874-882. PubMed ID: 37422678
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Song X; Kelley RK; Khan AA; Standifer N; Zhou D; Lim K; Krishna R; Liu L; Wang K; McCoon P; Negro A; He P; Gibbs M; Kurland JF; Abou-Alfa GK
Clin Cancer Res; 2023 Feb; 29(4):754-763. PubMed ID: 36477555
[TBL] [Abstract][Full Text] [Related]
10. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
11. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Planchard D; Reinmuth N; Orlov S; Fischer JR; Sugawara S; Mandziuk S; Marquez-Medina D; Novello S; Takeda Y; Soo R; Park K; McCleod M; Geater SL; Powell M; May R; Scheuring U; Stockman P; Kowalski D
Ann Oncol; 2020 May; 31(5):609-618. PubMed ID: 32201234
[TBL] [Abstract][Full Text] [Related]
12. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
Ogasawara S; Koroki K; Makishima H; Wakatsuki M; Takahashi A; Yumita S; Nakagawa M; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Sakuma T; Fujita N; Kojima R; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Ozawa Y; Kawasaki Y; Kurokawa T; Hanaoka H; Tsuji H; Kato N
BMJ Open; 2022 Apr; 12(4):e059779. PubMed ID: 35396315
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
He JZ; Duval V; Jauslin P; Gonçalves A; Abegesah A; Fan C; Lim K; Song X; Chen C; Shi X; Mann H; Krug L; Ren S; Phipps A; Gibbs M; Zhou D
Clin Pharmacol Ther; 2023 Dec; 114(6):1375-1386. PubMed ID: 37777827
[TBL] [Abstract][Full Text] [Related]
16. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G; Rizvi NA; Schmid P; Syrigos K; Martin C; Yamamoto N; Cheng Y; Moiseyenko V; Summers Y; Vynnychenko I; Lee SY; Bryl M; Zer A; Erman M; Timcheva C; Raja R; Naicker K; Scheuring U; Walker J; Mann H; Chand V; Mok T;
J Thorac Oncol; 2023 Jan; 18(1):106-119. PubMed ID: 36240972
[TBL] [Abstract][Full Text] [Related]
17. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.
Ahmed Z; Lee SS; Victor DW; Kodali S
J Hepatocell Carcinoma; 2023; 10():1911-1922. PubMed ID: 37915617
[TBL] [Abstract][Full Text] [Related]
18. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
19. Tremelimumab (Imjudo) for metastatic NSCLC.
Med Lett Drugs Ther; 2023 Feb; 65(1669):e31-e32. PubMed ID: 36757354
[No Abstract] [Full Text] [Related]
20. [New drugs approval: Durvalumab and tremelimumab as first line in the unresecable hepatocellular carcinoma].
Pureur D; Edeline J
Bull Cancer; 2023; 110(7-8):741-742. PubMed ID: 37032217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
